Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of low tumor burden, CD20-positive follicular lymphoma~* Ann Arbor Stage II, III, or IV~Exclusion Criteria:~* Not a candidate for treatment with rituximab as a single-agent~* Evidence of transformation to a high grade or diffuse large B-cell lymphoma~* Any previous systemic therapy for B-cell NHL, including chemotherapy, immunotherapy, or steroids~* Any prior treatment with rituximab~* Active, uncontrolled infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-05280586 (Type: EXPERIMENTAL): None
- MabThera® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).